Lumakras (sotorasib) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
58 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lumakras (sotorasib) / Amgen
ROSIE, NCT06314763: Rivaroxaban Sotorasib Interaction Study

Completed
4
21
Europe
Rivaroxaban 20mg, Xarelto, Sotorasib 960mg, Lumykras
Radboud University Medical Center, Amgen
Drug Drug Interaction Study
03/24
03/24
2020-005279-11: AMG 510 Expanded Access Protocol in Selected European Countries Protocollo di accesso allargato su AMG 510 in Paesi europei selezionati

Ongoing
3
638
Europe
AMG 510, [AMG 510], Film-coated tablet
AMGEN INC., Amgen, Inc., Amgen Inc
Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation Carcinoma polmonare non a piccole cellule localmente avanzato e non resecabile o metastatico con mutazione KRAS p.G12C precedentemente trattato, Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation Carcinoma polmonare non a piccole cellule localmente avanzato e non resecabile o metastatico con mutazione KRAS p.G12C precedentemente trattato, Diseases [C] - Cancer [C04]
 
 
CodeBreak 200, NCT04303780 / 2019-003582-18: Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) ().

Checkmark Data from CodeBreak 200 trial in combination with docetaxel for NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 200 trial in combination with docetaxel for NSCLC at ESMO 2022
Active, not recruiting
3
345
Europe, Canada, Japan, US, RoW
AMG 510, Docetaxel
Amgen
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
08/22
04/26
CodeBreaK 301, NCT06252649: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Recruiting
3
450
Europe, Japan, US, RoW
FOLFIRI Regimen, Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Bevacizumab-awwb, MVASI
Amgen
Metastatic Colorectal Cancer
09/27
04/31
Krascendo 1, NCT06497556: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
320
Europe, Japan, US, RoW
Divarasib, Sotorasib, Adagrasib
Hoffmann-La Roche, Chugai Pharmaceutical
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
09/26
09/29
CodeBreak 300, NCT05198934 / 2021-004008-16: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Jul 2023 - Dec 2023: Data readout from CodeBreak 300 trial for colorectal cancer
Active, not recruiting
3
160
Europe, Japan, US, RoW
Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Trifluridine and Tipiracil, Lonsurf, Regorafenib, Stivarga
Amgen
Colorectal Cancer (CRC)
03/25
03/25
CodeBreaK 202, NCT05920356: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Sotorasib, AMG 510, LUMYKRAS ®, LUMAKRAS ®, Pembrolizumab
Amgen
Non-Small Cell Lung Cancer (NSCLC)
02/26
03/31
SCARLET, jRCT2051210086: A Phase II Study of sotorasib + carboplatin + pemetrexed in patients with non-squamous and non-small cell lung cancer who are KRAS G12C mutation-positive chemotherapy naïve and progressively relapsed: A Study (WJOG14821L)

Active, not recruiting
2
30
Japan
Lumakras (sotorasib) - Amgen, pemetrexed - Generic mfg., carboplatin - Generic mfg.
Wakayama Medical University Hospital
Non small cell lung cancer
 
 
ACTRN12622000973718: SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation

Recruiting
2
52
 
The University of Sydney, Amgen Australia Pty Limited
advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
 
 
2021-001696-16: Sotorasib in patients with non-small cell lung cancer with genetic changes with comorbidities

Ongoing
2
100
Europe
sotorasib, AMG510, Tablet
Vestre Viken Health Trust, Vestre Viken Health Trust, Amgen
advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities, lung cancer with specific gene alteration/mutation in the KRAS gene, Diseases [C] - Cancer [C04]
 
 
2021-004576-34: A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRAS mutation and not eligible for chemotherapy treatment Un estudio de investigación para evaluar la actividad de Sotorasib para el tratamiento de pacientes con cáncer de pulmón no microcítico no operables con mutación KRAS y no elegibles para tratamiento con quimioterapia.

Not yet recruiting
2
43
Europe
Sotorasib, AMG 510, Tablet, LUMYKRAS
Fundación GECP, Fundación GECP
Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer Cáncer de pulmón no microcítico estadio III (IIIA-N2, IIIB, IIIC) KRAS p.G12C no resecables, Lung cancer called "non-small cell lung cancer (NSCLC)" not operable with KRAS mutation Cáncer de pulmón llamado "cáncer de pulmón no microcítico (CPNM)" no operable con mutación KRAS, Diseases [C] - Cancer [C04]
 
 
2021-006958-31: An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic non-small-cell lung cancer

Not yet recruiting
2
40
Europe
Sotorasib, AMG 510, Film-coated tablet, Lumykras
Gustave Roussy, AMGEN
Locally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutation, Locally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutation, Diseases [C] - Cancer [C04]
 
 
2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies

Not yet recruiting
2
46
Europe
RMC-4630 - 20 mg, LUMYKRAS, RMC-4630 - 100 mg, RMC-4630, Sotorasib, Capsule, Tablet, -, Sotorasib, RMC-4630
Revolution Medicines, Inc., Revolution Medicines
Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Diseases [C] - Cancer [C04]
 
 
2021-002638-18: Clinical study to investigate the safety, efficacy and pharmacokinetics of sotorasib in Subjects with Non-Small Cell Lung Cancer

Not yet recruiting
2
170
Europe
Sotorasib, AMG 510, Tablet, Lumykras
Amgen Inc., AMGEN INC., Amgen Inc.
KRAS p.G12C mutant untreated stage IV Non-Small Cell Lung Cancer (NSCLC), Non-small cell lung cancer, Diseases [C] - Cancer [C04]
 
 
CODEBREAK-IGR, NCT05631249 / 2021-006958-31: Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Recruiting
2
40
Europe
Sotorasib 120Mg Tab
Gustave Roussy, Cancer Campus, Grand Paris, AMGEN
KRAS P.G12C, Non Small Cell Lung Cancer
12/24
06/27
NCT05993455: A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab

Active, not recruiting
2
24
RoW
Oral sotorasib + IV Panitumumab
Korea University Anam Hospital
Efficacy
09/23
12/23
RMC-4630-03, NCT05054725 / 2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Active, not recruiting
2
47
Europe, Canada, US, RoW
RMC-4630, SAR442720, Sotorasib, AMG 510, Lumakras
Revolution Medicines, Inc., Sanofi, Amgen
Non-Small Cell Lung Cancer
09/23
03/24
2022-003564-24: Study to investigate JAB-3312 Combination Therapies in Adult Patients with Advanced Solid Tumors

Terminated
2
20
Europe
JAB-3312, JAB-3312, Capsule, Tablet, Lumykras
Jacobio Pharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Tumors, Solid Tumors, Diseases [C] - Cancer [C04]
 
 
NCT05400577: Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Withdrawn
2
25
US
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Fox Chase Cancer Center
Non-Small Cell Lung Cancer
01/24
02/24
ACTRN12621001690842: Cancer Molecular Screening and Therapeutics (MoST) Program Addendum 19 substudies 41-42: Sotorasib

Active, not recruiting
2
32
 
The University of Sydney, Office for Health and Medical Research, Australian Genomic Cancer Medicine Centre (AGCMC)
Cancer
 
 
NCT06333678: A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
160
US
Durvalumab, Sotorasib
Memorial Sloan Kettering Cancer Center, Amgen
Non-Small Cell Lung Cancer
03/27
03/27
NCT06582771: A Study of Sotorasib in People with Non-Small Cell Lung Cancer

Recruiting
2
39
US
Sotorasib
Memorial Sloan Kettering Cancer Center
Non Small Lung Cancer
08/26
08/26
SOLUCOM, NCT05311709: Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

Recruiting
2
100
Europe
sotorasib
Vestre Viken Hospital Trust, Aarhus University Hospital, Oslo University Hospital, Rigshospitalet, Denmark, Odense University Hospital, Karolinska University Hospital, University Hospital of North Norway, Haukeland University Hospital, St. Olavs Hospital
Lung Cancer, NSCLC, Stage III, NSCLC Stage IV, Lung Cancer Stage IV, Mutation, Cancer, Cancer, Lung
10/24
03/25
CodeBreaK 201, NCT04933695 / 2021-002638-18: A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Active, not recruiting
2
42
Europe, US, RoW
Sotorasib, AMG 510, LUMYKRAS, LUMAKRAS
Amgen, Amgen Inc.
Non-small Cell Lung Cancer
01/26
01/26
NCT05815186: Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Withdrawn
2
28
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
04/25
04/26
UNICORN, NCT05845450: Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer

Recruiting
2
112
Europe
Trastuzumab deruxtecan, Durvalumab, Panitumumab, Botensilimab, Balstilimab, Sotorasib
Gruppo Oncologico del Nord-Ovest
Colorectal Cancer, Resectable Colorectal Carcinoma
05/25
05/28
NCT05118854: A Phase II Study of Neoadjuvant Sotorasib in Combination with Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS P.G12C Mutation

Recruiting
2
27
US
AMG 510, Cisplatin, Platinol®-AQ, Platinol®, CDDP, Carboplatin, Pemetrexed, LY231514, Alimta®, MTA, Multitargeted Antifolate, NSC-698037
M.D. Anderson Cancer Center, Amgen
Lung Cancer
10/25
10/25
NCT05638295: Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Recruiting
2
105
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
12/25
12/25
NCT05451056: An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

Not yet recruiting
2
37
RoW
sotorasib
Yonsei University
Non Small Cell Lung Cancer
01/26
02/26
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC

Withdrawn
2
47
Europe
Sotorasib, Lenvatinib
ETOP IBCSG Partners Foundation, Amgen, Eisai Inc.
Metastatic Non Small Cell Lung Cancer, KRAS G12C
09/26
12/26
ECOG-ACRIN LUNG-MAP SUB-STUDY, NCT04625647: Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Active, not recruiting
2
116
US, RoW
Sotorasib, AMG 510, AMG-510, AMG510
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/26
12/27
MERIT-lung, NCT05398094 / 2021-004576-34: Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Recruiting
2
43
Europe
Sotorasib, AMG510
Fundación GECP, Fundación GECP
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
12/27
12/28
NCT05564377: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
2
2900
US
Alpelisib, BYL 719, BYL-719, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ICI-182780, ICI182780, ZD 9238, ZD-9238, ZD9238, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Nilotinib Hydrochloride Monohydrate, AMN 107, AMN-107, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
07/30
07/30
2020-004721-23: Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

Not yet recruiting
1/2
1200
Europe
Sotorasib, Panitumumab, palbociclib, AMG 510, AMG 954, Film-coated tablet, Concentrate for solution for infusion, LUMYKRAS, Vectibix 20mg/ml concentrate for solution for infusion, IBRANCE
Amgen Inc., AMGEN INC., Amgen Inc, Amgen Inc.
Advanced Solid Tumors with KRAS p.G12C Mutation, Advanced Solid Tumors with KRAS p.G12C Mutation, Diseases [C] - Cancer [C04]
 
 
NCT05180422: A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Withdrawn
1/2
43
US
AMG 510, MVASI
Criterium, Inc., Amgen
Non Small Cell Lung Cancer
01/23
01/23
NCT05251038: Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Withdrawn
1/2
59
US
Sotorasib, Lumakras, Liposomal Irinotecan (nal-IRI), Onivyde, 5 Fluorouracil (5FU), Leucovorin (LV), Gemcitabine (GEM), Nab paclitaxel, Abraxane
Devalingam Mahalingam, Amgen
Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
01/23
01/23
NCT05313009: Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Terminated
1/2
5
US
Sotorasib and Tarloxotinib
Medical University of South Carolina, Rain Oncology Inc
Non-Small Cell Lung Cancer
07/23
12/23
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
NCT04720976 / 2022-003564-24: JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
200
US
JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib
Jacobio Pharmaceuticals Co., Ltd., AbbVie
Solid Tumor, NSCLC
01/24
02/24
NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
144
US
DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
CodeBreak 100, NCT03600883 / 2018-001400-11: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
Checkmark Approved in Japan for the treatment of KRAS G12C-mutated 2L NSCLC
Jan 2022 - Jan 2022: Approved in Japan for the treatment of KRAS G12C-mutated 2L NSCLC
Checkmark Granted conditional marketing authorization for LUMYKRAS for 2L treatment of adults with advanced NSCLC with KRAS G12C mutation
More
Active, not recruiting
1/2
713
Europe, Canada, Japan, US, RoW
sotorasib, Anti PD-1/L1, Midazolam
Amgen
KRAS p.G12C Mutant Advanced Solid Tumors
05/28
05/28
NCT05374538: VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Terminated
1a/1b
4
US
VIC-1911, sotorasib, LUMAKRAS
Vitrac Therapeutics, LLC, Westat
Non-small Cell Lung Cancer
08/23
08/23
HERKULES-2, NCT04959981: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed
1b
24
US
ERAS-007, ERAS-601, Osimertinib, Tagrisso, Sotorasib, Lumakras
Erasca, Inc.
Advanced Non-squamous Non-small-cell Lung Cancer
04/23
04/23
NCT04380753: AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Active, not recruiting
1
12
RoW
AMG 510
Amgen
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
12/21
06/25
NCT05036291: A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1
120
US
NB004 tablets, Sotorasib
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
02/25
06/25
K-SAB, NCT06127940: Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation

Recruiting
1
20
Europe
Stereotactic body radiation therapy (SBRT), Sotorasib, Temporary Stopping
Karolinska University Hospital, Sahlgrenska University Hospital, Sweden, Amgen
Non-small Cell Lung Cancer Metastatic
06/25
01/26
NCT06061523: A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants

Withdrawn
1
140
NA
Sotorasib, AMG 510
Amgen
Healthy Participants
09/24
09/24
NCT06249282: Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
1
15
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
03/26
03/26
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
NCT06333951: AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Recruiting
1
500
Japan, US, RoW
AMG 193, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Amgen
Thoracic Tumors, Non-small Cell Lung Cancer
10/28
10/31
NCT06659341: A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Recruiting
1
104
Europe, RoW
BAY3498264
Bayer
Advanced Solid Tumors Harboring KRAS G12C Mutation
01/27
11/27
NCT05815173: Ladarixin With Sotorasib in Advanced NSCLC

Recruiting
1
40
US
Sotorasib, Ladarixin
NYU Langone Health
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
08/25
08/26
CodeBreak101, NCT04185883 / 2020-004721-23: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen, Amgen Inc, Amgen Inc.
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
04/26
03/28
Lung KG12Ci, NCT05273047: RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Active, not recruiting
N/A
458
Europe
Intergroupe Francophone de Cancerologie Thoracique, Amgen
Nsclc, KRAS P.G12C
08/23
12/24
NCT04667234: Expanded Access of Sotorasib

No Longer Available
N/A
US, RoW
AMG 510, Sotorasib, Lumakras (US), Lumykras (UK)
Amgen
Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
 
 
ChiCTR2300070135: Clinical study of 18F-AMG510 PET/CT imaging in the accurate diagnosis of tumor KRAS mutations

Recruiting
N/A
 
Xijing Hospital; Xijing Hospital, the National Natural Science Foundation of China: 91959208
Tumor
 
 
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting
N/A
80
Europe
Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
09/26
09/26

Download Options